Sign up Australia
Proactive Investors - Run By Investors For Investors

MaxCyte hails US National Institutes of Health tie-up to find treatment for sickle cell disease

The collaboration will be with National Heart, Lung and Blood Institute, which is part of the NIH
microscope
The pair will use MaxCyte's cell engineering platform

MaxCyte Inc (LON:MXCT) shares rose on Monday after it said it has entered into an R&D agreement with the US National Institutes of Health (NIH) to develop treatments for sickle cell disease. 

They will do so using next-generation CRISPR/Cas9-based single-nucleotide correction technologies enabled by MaxCyte's cell engineering platform.

The collaboration will be with National Heart, Lung and Blood Institute, which is part of the NIH.

Correcting mutations

The two hope to "correct" the faulty haemoglobin gene that causes the disease and address DNA mutations that contribute to the disease. 

As part of the tie-up, MaxCyte will supply messenger RNA molecules that convey genetic information from DNA to the ribosomes.

It will also use its Flow Electroporation Technology to develop reliable and effective processes to correct gene sequences.

MaxCyte chief executive Doug Doerfler said: "We believe that this work will further validate our platform for developing gene-editing therapies for a broad range of diseases while enabling rapid, development and commercial manufacturing of new therapies for patients where there is an extremely high unmet medical need."

In early morning trading, Maxcyte shares were up 1.6% at 249p.

-- Adds share price --

 

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018
Article
October 10 2018

Related Articles

bacteria
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
cough
October 19 2018
Respiratory syncytial virus causes the common cold, for which there is no effective cure.
pills
July 26 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use